Novo Nordisk CEO Sees Demand for Better Products

The transcript discusses the company's earnings, market reaction, and performance, highlighting a 4% growth in the first half of 2018. It addresses US pricing pressures, including comments from President Trump, and the impact on drug pricing and Medicare codes. The company emphasizes its innovation in diabetes drugs and market share growth, particularly in the US and internationally. The M&A strategy focuses on biopharma, with challenges due to high valuations and cash availability.

What was the growth percentage reported by the company for the first half of 2018?

• 3%

• 4%

• 6%

• 5%

What is the company's perspective on the US pricing situation?

• They believe prices will remain stable.

• They expect prices to increase significantly.

• They anticipate continued price pressure.

• They foresee a decrease in price pressure.

How much market share did the company capture with its new product launch in the first half of 2018?

• 20%

• 25%

• 15%

• 10%

What is the company's approach to maintaining access to its products in the US?

• Focusing solely on international markets.

• Limiting access to exclusive markets.

• Maintaining broad access to promote new innovations.

• Reducing product prices significantly.

What is the company's strategy regarding M&A in the current market environment?

• Focus on aggressive expansion regardless of cost.

• Engage in M&A only in the US market.

• Prioritize M&A in the biopharma sector while being cautious with valuations.

• Avoid M&A due to high market prices.